Skip To Main Content
Ella I Ertekin on Muck Rack

Ella I Ertekin

Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Ella I

Contact Ella I, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Thrombin generation to predict breakthrough bleeding in patients with acquired hemophilia A under emicizumab prophylaxis

|
By Fabius J Pelzer, Ella I Ertekin, Olga Oleshko, Annika Klingberg
| tu-dresden.de
Acquired hemophilia A (AHA) is a serious bleeding disorder due to neutralizing autoantibodies against factor VIII (FVIII). Emicizumab mimics the activity of FVIIIa restoring thrombin generation. It was shown to protect patients with AHA from bleeding, but some patients experience clinically relevant breakthrough bleeding. Therefore, monitoring the efficacy of emicizumab might be useful, potentially through thrombin generation assay (TGA).
Open in Who Shared Issue with article?
See all 1 articles